Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Remibrutinib
Novartis Pharmaceuticals
Chronic Inducible Urticaria
1 trial -
Remternetug, Placebo to match LY
Eli Lilly Co.
Alzheimerβs Disease
1 trial -
Resmetirom
Madrigal Pharmaceuticals EU Limited
Non-Alcoholic Fatty Liver Disease
1 trial -
Resmetirom
Madrigal Pharmaceuticals EU Limited
NASH
1 trial -
Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)
Incyte
Squamous Carcinoma of the Anal Canal
1 trial -
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa
Sanofi-aventis Healthcare Pty Ltd
Plasma cell myeloma
1 trial -
Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s
Incyte
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
1 trial -
Revumenib
Syndax Pharmaceuticals
Acute Myeloid Leukemias
1 trial -
Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib
Syndax Pharmaceuticals
Newly Diagnosed AML with an NPM1 mutation
1 trial -
Ribavirin
Vertex Pharmaceuticals (Australia) Pty.
Genotype 1 Chronic Hepatitis C
1 trial -
Ribociclib
Novartis Pharmaceuticals
Breast Cancer
1 trial -
Ribociclib
Novartis Pharmaceuticals
Advanced, Metastatic Breast Cancer
1 trial -
Rilonacept
Regeneron UK Limited
Acute Gout Flare
1 trial -
Rilonacept
Kiniksa Pharmaceuticals International, plc
Recurrent Pericarditis
1 trial -
Rilonacept
Regeneron UK Limited
Gout
3 trials -
Rilonacept 80 mg
Regeneron UK Limited
Intercritical Gout
1 trial -
Rilzabrutinib, Composition of placebo is identical to that of IMP except that 400mg active ingredient is replaced with 400mg mannitol.
Lacuna Pharma Pty Ltd
Immune Thrombocytopenia (ITP)
1 trial -
Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate
Pfizer Australia Pty Ltd
Migraine (with or without aura)
1 trial -
Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg
Pfizer Australia Pty Ltd
Alopecia areata
1 trial -
Rivaroxaban
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation
1 trial -
Rivaroxaban 2.5 mg
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Coronary Syndrome
1 trial -
Rocatinlimab, Placebo for AMG 451
Amgen
Prurigo Nodularis
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources